Inactive Instrument

Clinigen Group plc

Equities

CLIN

GB00B89J2419

Clinigen : Capital Markets Day

November 28, 2018 at 02:21 am EST

28 November 2018

Capital Markets Day

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global pharmaceuticals and services company, is holding a Capital Markets Day for institutional investors and analysts today in London.

The event is being hosted by Shaun Chilton, Group Chief Executive Officer, and will include presentations by senior executives, including representatives from each of the Group's three businesses - Clinical Trial Services, Unlicensed Medicines and Commercial Medicines.

The presentations will cover a number of areas, including:

 The market dynamics affecting each business and how the respective strategies are evolving to meet customers' demands and provide long term growth
 How the Group's businesses are working in ever greater alignment to provide a continuation of specialised support throughout the lifecycle of a product
 How Clinigen's buy and build strategy along with its digital strategy is creating a global infrastructure to support each business and the Group's future growth

No new material information will be provided.

A copy of the presentations and an audio recording of the day will be made available on the Group's website atwww.clinigengroup.com shortly after the event.

- Ends -

Contact Details

Clinigen Group plc	Tel: +44 (0) 1283 495010
Shaun Chilton, Group Chief Executive Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited	Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
RBC Capital Markets - Joint Broker	Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners	Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne Sewell / Alex Shaw	Email:clinigen@instinctif.com
About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliverthe right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visitwww.clinigengroup.com

Attachments

Original document
Permalink

Disclaimer

Clinigen Group plc published this content on 28 November 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 28 November 2018 07:20:03 UTC

Latest news about Clinigen Group plc

Clinigen Launches NaviGATE an Educational Programme for Rare Disease Patients and Organizations	23-09-12	CI
CNX Therapeutics Limited acquired Cardioxane® (dexrazoxane), Savene® (dexrazoxane), Totect® (dexrazoxane) and Ethyol®, four cancer support therapies from Clinigen Limited.	23-08-09	CI
Clinigen Limited Reports Earnings Results for the Full Year Ended June 30, 2022	23-05-08	CI
Adragos Pharma GmbH completed the acquisition of Lamda Laboratories S.A. from Clinigen Limited.	23-04-02	CI
Adragos Pharma GmbH signed a definitive agreement to acquire Lamda Laboratories S.A. from Clinigen Limited.	23-03-19	CI
Iovance Biotherapeutics, Inc. entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited for approximately £210 million.	23-01-22	CI
Clinigen Group plc acquired Drug Safety Navigator, LLC.	22-12-30	CI
Clinigen Notes Results from the MIROCALS Trial Investigating Low Dose Proleukin® (Aldesleukin) in Patients with Amyotrophic Lateral Sclerosis	22-12-08	CI
Clinigen Group plc agreed to acquire Drug Safety Navigator, LLC.	22-11-28	CI
Clinigen Expands US Site Capacity in Response to Growing Demand for Clinical Supplies Management Services	22-05-24	CI
Triton Funds Company Completes Takeover Of Clinigen	22-04-04	MT
Triton Fund V SCSP, Triton Fund V L.P., Triton Fund V F&F No. 5 SCSp, Triton Fund V F&F No.3 L.P., Triton Fund V F&F L.P., Triton Fund V F&F No. 2 L.P., Triton Fund V F&F 4 SCSp and Triton C Investment A L.P., managed by Triton completed the acquisition of Clinigen Group plc.	22-04-03	CI
UK's High Court Approves Clinigen's Takeover	22-03-31	MT
Clinigen's Fiscal H1 Profit Sinks As Sales, Administrative Costs Rise	22-02-23	MT
Clinigen Group plc Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-23	CI
Scentre Group CEO/Managing Director to Step Down End-September; Shares Fall 5%	22-02-22	MT
Scentre Signals Higher Distribution, Faster Earnings Growth in Fiscal Year 2022	22-02-22	DJ
Clinigen Expects to Complete $1.8 Billion Sale to Triton in Early April	22-02-16	MT
Clinigen Group plc Signs Distribution Agreement with Deciphera Pharmaceuticals	22-02-09	CI
Clinigen Group Declares the Voting Results	22-02-08	CI
Clinigen Group plc Issues Open Letter to the Shareholders	22-01-20	CI
Clinigen Postpones Court, General Meetings following Increased Takeover Offer	22-01-18	MT
Global markets live: Credit Suisse, Unilever, Pfizer, Volkswagen, Triton...	22-01-17
UK's Clinigen agrees to sweetened $1.8 billion Triton take-private deal	22-01-17	RE
Clinigen Receives Sweetened $1.8 Billion Takeover Bid From Triton	22-01-17	MT

Chart Clinigen Group plc

Duration

Period

More charts

Company Profile

Clinigen Group plc is a United Kingdom-based pharmaceutical services and products company. The Company's principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. It operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). It operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.

Sector

More about the company